Skip to content
FibonacciAestheticsLog inTry it free

Practice regulations

The obligations of the doctor who uses a medical device: labelling, traceability and reporting an incident

What falls to the doctor who uses a medical device or an aesthetic product under Annex XVI: who is who, UDI and traceability, reporting of a serious incident.

The Fibonacci editorial teamUpdated on 8 min read

Medical monitor showing vital signs
In this article
  1. Who is who in the regulation
  2. Label and instructions: what to ask the supplier
  3. UDI and traceability
  4. Expected reaction or incident
  5. Who it is reported to
  6. What is written in the record and what leaves the practice

Under the European medical devices regulation, a doctor who uses a device on a patient is a «user»: any healthcare professional or lay user who uses a device. The heaviest responsibilities (CE marking, label, instructions, UDI identifier, surveillance) lie with the manufacturer. Those working in a practice are directly affected by three things: reporting a serious incident, even a suspected one; recording and storing the UDI of the devices received, in the ways that ministerial decrees have yet to set out; and being able to say what was used and on whom.

For fillers, lasers and pulsed lights the regulation applies, from the date of application of the common specifications, even if the product has no medical purpose. For botulinum toxin it does not: it is a medicinal product, and has its own rules.

Who is who in the regulation

Article 2 of the regulation defines the figures in the chain (consolidated text (opens in a new tab)):

FigureWho they areWhat they do that concerns you
ManufacturerWhoever manufactures or refurbishes a device, or has it designed and manufactured, and markets it under their own name or trademarkCE marking, label, instructions, UDI; reports serious incidents to the authorities (art. 87)
ImporterWhoever, established in the Union, places on the market a device coming from a third countryChecks CE marking, label, instructions and UDI before placing it on the market (art. 13, para. 2)
DistributorWhoever, in the supply chain and other than the manufacturer and importer, makes a device available until it is put into serviceChecks CE marking, manufacturer's information and UDI before making it available (art. 14, para. 2)
UserAny healthcare professional or lay user who uses a deviceThat is you

A «health institution» is another figure: an organisation whose primary purpose is the care or treatment of patients or the promotion of public health. For the UDI the regulation addresses health institutions, and the Italian decree also names healthcare professionals: for those working in a practice the substance does not change.

Fillers and aesthetic lasers are included because Article 1 extends the regulation to the groups of products without a medical purpose listed in Annex XVI and, for the purposes of the text, calls them all «devices» (paras 2 and 4). The European MDCG 2023-5 guidance adds that for these products there is no definition and the descriptions of the groups in the Annex are used (MDCG 2023-5 (opens in a new tab)). Botulinum toxin is outside: Article 1, paragraph 6, point (b), excludes medicinal products. The overview of the list is in the article on Annex XVI.

Label and instructions: what to ask the supplier

Label and instructions are the manufacturer's job, and importers and distributors must check them before circulating the product: CE marking and declaration of conformity, information provided by the manufacturer, UDI if one has been assigned. Before buying a filler or a device, these are the things you can ask the supplier.

For fillers, Implementing Regulation 2022/2346 requires the label to state, in bold and in the largest font size used, the wording «To be administered exclusively by healthcare professionals appropriately trained, qualified or accredited in accordance with national legislation», and the indication that the product must not be used under 18 years of age; the instructions must contain detailed technical information for administration and a patient leaflet (Annex IV, points 5 and 6 (opens in a new tab)). Keeping the label and instructions of what you use is a matter of prudence: they are the documents with which, in the event of a dispute, you answer the question «what did you use, and according to which instructions».

UDI and traceability

The regulation, in Article 27, paragraph 9, obliges health institutions to record and store the UDIs of class III implantable devices. For other devices, Member States encourage health institutions, and may oblige them, to do so, and encourage healthcare professionals, and may oblige them.

In Italy, Italian Legislative Decree 137/2022, in Article 15 (opens in a new tab), paragraph 1, establishes that health institutions and healthcare professionals are required to record and store the UDI of the devices they have received, in accordance with provisions to be laid down by decrees of the Minister of Health. Here too the text refers elsewhere: check on the Ministry's portal whether the decrees have been adopted and what they require.

On the suppliers' side, Article 25 of the regulation says that economic operators must be able to identify, for the authority, any health institution or healthcare professional to whom they have directly supplied a device. Whoever sells you the product knows they sold it to you: keep invoices and purchase orders.

How the lot is written, how it is read from the code on the packaging and how to respond to a recall is in the article on lot traceability. In Fibonacci, recording a session has the fields lot, expiry and optional UDI, and Leggi dalla confezione derives lot, expiry, serial number and product code from the 2D code; on the Magazzino page the Chi l'ha ricevuto tab searches by lot across all records (recording a treatment, stock).

Expected reaction or incident

The regulation distinguishes. An «incident» is any malfunction or deterioration in the characteristics or performance of a device made available on the market, including a use error due to ergonomic features, any inadequacy in the manufacturer's information and any undesirable side effect. It is «serious» if it has caused, may have caused or may cause the death, a serious deterioration, temporary or permanent, in the state of health of a person, or a serious threat to public health (art. 2, points 64 and 65).

The manufacturer does not report as serious incidents the expected side effects, those clearly documented in the product information and quantified in the technical documentation: they go in trend reports (art. 87, para. 1, and art. 88). That is why it is worth having read the instructions: they say which effects the manufacturer considers expected.

The Italian decree has two levels. For a serious incident, even a suspected one, reporting to the Ministry is an obligation (art. 10, paragraph 2). For an incident that is not serious, healthcare professionals, lay users and patients may report it (paragraph 3). The decree says «medical device»: aesthetic fillers and lasers are devices under the European regulation but have no medical purpose, so in the ministerial decree in force check what it covers.

You judge the seriousness, in the specific case, using the definitions above and your examination of the patient. After your report, the authority informs the manufacturer; if the latter considers that the incident is not serious, or that it is an expected effect, it provides a clarifying justification, and the authority may require a report (art. 87, para. 11).

Who it is reported to

Paragraph 2 of Article 10 indicates the Ministry of Health. Paragraph 4 says that the report is made by the healthcare professional directly or through the health facility involved, in compliance with national rules and any regional provisions that designate vigilance contacts. Paragraph 5 adds that it must also be sent to the manufacturer or its authorised representative, including through the distributor. Complaints (paragraph 6) are reported to the manufacturer, and the Ministry is informed at the same time.

The legislative decree does not set out the terms: the answer to «within how many days?» is in the ministerial decree in force. Look at it on the Ministry's portal before you need it, not on the day of the event. The manufacturer's terms, on the other hand, are written in the regulation, and explain why your report matters: immediately after establishing the link, even a reasonably possible one, and in any case no later than 15 days from when it became aware of the incident; within 10 days in the event of death or an unexpected serious deterioration in health; within 2 days in the event of a serious threat to public health (art. 87, paras 3, 4 and 5).

What is written in the record and what leaves the practice

WhereWhat
In the recordThe event in the patient's words; the date and time you observed it; the seriousness you chose; product, lot, UDI; what you did; the outcome; the date of the report and who it went to
OutsideThe report to the Ministry; the copy to the manufacturer or authorised representative, including through the distributor; complaints to the manufacturer

In Fibonacci the complication is recorded from the session line, so that it stays linked to product and lot, and next to each complication appears Scheda di segnalazione, which prepares the text to be copied into the Ministry's form. When you record the complication the system opens a reminder in Attività, with the deadline calculated from the required terms. The form transmits nothing, does not decide whether the incident is serious (it reads the seriousness you recorded) and reports the event and the product, not the patient's data. The form also reminds you that recording a complication is not a pharmacovigilance report: they are two different channels, with different recipients (outcomes and complications). How to recheck a patient after a treatment is in the article on follow-up after treatment; what to document after a complication is in the guide after a complication.

What Fibonacci does for this

This is how it looks in Fibonacci, with sample data:

Sessions with product and batch in Fibonacci, with sample data

Sources

  1. Regulation (EU) 2017/745 (MDR), consolidated text as at 9 July 2024 (EUR-Lex) (opens in a new tab)
  2. Italian Legislative Decree No. 137 of 5 September 2022, Articles 10 and 15 (Normattiva) (opens in a new tab)
  3. MDCG 2023-5, Guidance on qualification and classification of Annex XVI products, December 2023 (opens in a new tab)
  4. Commission Implementing Regulation (EU) 2022/2346, Annex IV, points 5 and 6 (EUR-Lex) (opens in a new tab)

These articles explain what regulations and guidelines require and what is documented in the medical record. They are not legal or tax advice on your situation and do not say how to treat a patient.

Try Fibonacci in your practice for 15 days, no credit card needed

Within one working day we call you: together we set up your practice and import your data.

Try it free

Read next

All articles